Who makes CD11301 0.03%?

CD11301 0.03% is developed by Galderma R&D.

Last reviewed 2026-04-23 · How we verify

CD11301 0.03%

Galderma R&D · Phase 2 active Small molecule

At a glance

Generic name	CD11301 0.03%
Sponsor	Galderma R&D
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CD11301 0.03% CI brief — competitive landscape report
CD11301 0.03% updates RSS · CI watch RSS
Galderma R&D portfolio CI